Stockscreener 앱 받기
0.00
100.00%
-15.02
전일 마감가:
$15.02
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$1.48B
수익:
$11.40B
순이익/손실:
$-95.73M
주가수익비율:
0.00
EPS:
-2.45
순현금흐름:
$-64.37M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$15.29
Definium Therapeutics Inc Stock (MNMD) Company Profile
명칭
Definium Therapeutics Inc
전화
212-220-6633
주소
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNMD
Definium Therapeutics Inc
|
0.00 | 1.48B | 11.40B | -95.73M | -64.37M | -2.45 |
VRTX
Vertex Pharmaceuticals Inc
|
436.83 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
742.73 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
793.73 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.76 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.88 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Definium Therapeutics Inc Stock (MNMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Stifel | Buy |
| 2026-04-10 | 개시 | Piper Sandler | Overweight |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-30 | 개시 | Jefferies | Buy |
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-08-04 | 재개 | Oppenheimer | Outperform |
| 2025-01-28 | 개시 | Evercore ISI | Outperform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-07-24 | 개시 | ROTH MKM | Buy |
| 2024-05-29 | 개시 | Robert W. Baird | Outperform |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | Canaccord Genuity | Buy |
| 2022-12-09 | 재개 | ROTH Capital | Buy |
| 2022-11-16 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-26 | 개시 | Oppenheimer | Outperform |
| 2022-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 개시 | ROTH Capital | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
모두보기
Definium Therapeutics Inc 주식(MNMD)의 최신 뉴스
DFTX Maintained by Leerink Partners -- Price Target Raised to $3 - GuruFocus
DFTX News Today | Why did Definium Therapeutics stock go up today? - MarketBeat
Definium Therapeutics (DFTX) Stock Gains After Hours: Here's What's Driving The Move - Benzinga
Definium Therapeutics Announces New Employee Inducement GrantsApril 20, 2026 - BioSpace
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $38 - Moomoo
Definium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst - MSN
Definium Therapeutics (DFTX) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Definium Therapeutics (DFTX) Stock Soars to New Heights on Trump’s Psychedelic Research Order - MEXC Exchange
Definium Therapeutics stock hits 52-week high at 25.63 USD - Investing.com
Definium Therapeutics (DFTX) Stock Hits 52-Week High as Trump Backs Psychedelic Medicine Research - CoinCentral
Definium Therapeutics (DFTX) Stock Soars to New Heights on Trump's Psychedelic Research Order - Blockonomi
Psychedelic Pharmaceutical Companies' Shares Rise Following Executive Order -- Update - Moomoo
Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On? - Benzinga
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - Seeking Alpha
Psychedelic drug makers rally as Trump orders FDA to expedite reviews - Yahoo Finance
Psychedelic stocks rally after Trump orders faster PTSD research; Compass Pathways, Atai lead gains - Seeking Alpha
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
Definium Therapeutics (DFTX) Is Up 5.3% After White House Signals Support For Psychedelic Research - simplywall.st
Definium Therapeutics (DFTX) Stock Climbs Following White House Psychedelic Policy Shift - MEXC
Definium Therapeutics (DFTX) Stock Rises as White House Moves on Psychedelic Treatments | MEXC News - MEXC Exchange
Definium Therapeutics (DFTX) Stock Rises as White House Moves on Psychedelic Treatments - MEXC
symbol__ Stock Quote Price and Forecast - CNN
Definium Therapeutics supports White House executive order on mental health innovation, committed to developing psychedelic treatments for mental health - marketscreener.com
Definium Therapeutics Supports White House Executive Order On Mental Health Innovation, Committed To Developing Psychedelic Treatments For Mental Health - TradingView
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments - The Joplin Globe
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026 - TechStock²
Trump signs executive order on psychedelics (ATAI:NASDAQ) - Seeking Alpha
Trump Trade: President to sign order on psychedelic used for PTSD - Yahoo Finance
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its Strong 1 Year Run? - Yahoo Finance
Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones (NASDAQ:DFTX) - Seeking Alpha
DFTX Initiates Coverage On Stifel -- Rating Set to Buy - GuruFocus
Can an LSD candidate do for anxiety what Spravato did for depression? - Pharma Voice
Stifel Initiates Definium Therapeutics at Buy With $30 Price Target - marketscreener.com
Definium Therapeutics Conference Slot Tests Psychedelic Phase III And Funding Story - Sahm
DFTX Maintains Buy Rating by Canaccord Genuity -- Price Target R - GuruFocus
Stifel initiates Definium stock with buy rating on anxiety drug - Investing.com UK
Stifel initiates Definium stock with buy rating on anxiety drug By Investing.com - Investing.com Australia
Definium Therapeutics Teases 3 Phase III DT120 Readouts in 2026, Starting Late Q2 MDD Data - MarketBeat
Definium Therapeutics Price Target Raised to $38.00/Share From $25.00 by Canaccord Genuity - Moomoo
Shroom stocks rise as Trump is said to sign executive order on psychedelic drug - Seeking Alpha
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics (NASDAQ:DFTX) Sets New 1-Year HighStill a Buy? - MarketBeat
DFTX Options Chain — NASDAQ:DFTX - TradingView
DFTX Options Volatility — NASDAQ:DFTX - TradingView
Definium Therapeutics Sees Insider Stock Selling - 富途牛牛
DFTX: Definium Therapeutics, Inc.Income Statment - Zacks Investment Research
All News for DFTX : Definium Therapeutics, Inc. - Zacks Investment Research
DFTX: Piper Sandler Initiates Coverage with Overweight Rating | - GuruFocus
Definium Therapeutics stock hits 52-week high at 21.99 USD - Investing.com
Definium Therapeutics stock hits 52-week high at 21.99 USD By Investing.com - Investing.com UK
Definium Therapeutics Inc (MNMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Definium Therapeutics Inc 주식 (MNMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sullivan Mark | Chief Legal Officer |
Mar 25 '26 |
Sale |
18.47 |
10,702 |
197,666 |
271,079 |
| Barrow Robert | Chief Executive Officer |
Mar 25 '26 |
Sale |
18.47 |
24,431 |
451,241 |
752,454 |
1.09%
0.42%
자본화:
|
볼륨(24시간):